Abstract
Meningococcal serogroup B (MenB) accounts for an important proportion of invasive meningococcal disease (IMD). The 4-component vaccine against MenB (4CMenB) is composed of factor H binding protein (fHbp), neisserial heparin-binding antigen (NHBA), Neisseria adhesin A (NadA), and outer membrane vesicles of the New Zealand strain with Porin 1.4. A meningococcal antigen typing system (MATS) and a fully genomic approach, genetic MATS (gMATS), were developed to predict coverage of MenB strains by 4CMenB. We characterized 520 MenB invasive disease isolates collected over a 5-year period (January 2007–December 2011) from all Australian states/territories by multilocus sequence typing and estimated strain coverage by 4CMenB. The clonal complexes most frequently identified were ST-41/44 CC/Lineage 3 (39.4%) and ST-32 CC/ET-5 CC (23.7%). The overall MATS predicted coverage was 74.6% (95% coverage interval: 61.1%–85.6%). The overall gMATS prediction was 81.0% (lower–upper limit: 75.0–86.9%), showing 91.5% accuracy compared with MATS. Overall, 23.7% and 13.1% (MATS) and 26.0% and 14.0% (gMATS) of isolates were covered by at least 2 and 3 vaccine antigens, respectively, with fHbp and NHBA contributing the most to coverage. When stratified by year of isolate collection, state/territory and age group, MATS and gMATS strain coverage predictions were consistent across all strata. The high coverage predicted by MATS and gMATS indicates that 4CMenB vaccination may have an impact on the burden of MenB-caused IMD in Australia. gMATS can be used in the future to monitor variations in 4CMenB strain coverage over time and geographical areas even for non-culture confirmed IMD cases.
Original language | English |
---|---|
Pages (from-to) | 3230-3238 |
Number of pages | 9 |
Journal | Human Vaccines and Immunotherapeutics |
Volume | 17 |
Issue number | 9 |
Early online date | 12 Apr 2021 |
DOIs | |
Publication status | E-pub ahead of print - 12 Apr 2021 |
Bibliographical note
Funding Information:Giuseppe Boccadifuoco, Duccio Medini, Davide Serruto, Marzia Monica Giuliani, Maria Stella, Rosita De Paola, Alessandro Muzzi, Mariagrazia Pizza and Michael D. Nissen are employees of the GSK group of companies. Marzia Monica Giuliani, Mariagrazia Pizza and Michael D. Nissen also hold shares in the GSK group of companies. David M. Whiley reports Research funding from Speedx Pty Ltd for diagnostic test development and validation, outside the submitted work. Ray Borrow reports performing contract research on behalf of Public Health England for the GSK group of companies for the conduct of the study. Ray Borrow also reports performing contract research for Pfizer and Sanofi Pasteur, outside the submitted work. Giuseppe Boccadifuoco, Duccio Medini, Davide Serruto, Marzia Monica Giuliani, Maria Stella, Rosita De Paola, Alessandro Muzzi, Mariagrazia Pizza, Michael D. Nissen, David M. Whiley and Ray Borrow declare no other financial and non-financial relationships and activities. Sarah J. Tozer, Helen V. Smith and Theo P. Sloots declare no financial and non-financial relationships and activities and no conflicts of interest.
Publisher Copyright:
© 2021 GlaxoSmithKline Biologicals S.A. Published with license by Taylor & Francis Group, LLC.
Keywords
- 4CMenB
- Australia
- MATS
- Meningococcal serogroup B
- gMATS
- strain coverage